Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Researchers discover unique structure and function of rotavirus VP3 protein

Researchers discover unique structure and function of rotavirus VP3 protein

Gimsilumab trial starts in first US patient with ARDS and COVID-19

Gimsilumab trial starts in first US patient with ARDS and COVID-19

Alzheimer's disease: high amyloid levels linked to early disease

Alzheimer's disease: high amyloid levels linked to early disease

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

Evinacumab drug reduces cholesterol levels in patients with rare cholesterol disorder

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

Monoclonal antibody reduces LDL cholesterol in adult patients with HoFH

UC Davis launches two clinical trials to evaluate treatments for COVID-19

UC Davis launches two clinical trials to evaluate treatments for COVID-19

Berkeley Lights Announces GEPAD to Attack COVID-19 and Other Viruses

Berkeley Lights Announces GEPAD to Attack COVID-19 and Other Viruses

Celltrion announces key milestones in its efforts to fight COVID-19

Celltrion announces key milestones in its efforts to fight COVID-19

New understanding of signaling molecule interleukin-2 can guide drug discovery efforts

New understanding of signaling molecule interleukin-2 can guide drug discovery efforts

New sepsis intervention enhances the body's bacteria-capturing neutrophil extracellular traps

New sepsis intervention enhances the body's bacteria-capturing neutrophil extracellular traps

New immunotherapeutic strategy shows promise to fight off infectious biofilms

New immunotherapeutic strategy shows promise to fight off infectious biofilms

Boosting immune cells to treat eczema

Boosting immune cells to treat eczema

Columbia teams receive $2.1 million grant to find potential antiviral drugs for 2019-nCoV

Columbia teams receive $2.1 million grant to find potential antiviral drugs for 2019-nCoV

Simple, portable test can detect poisonous mushrooms in minutes

Simple, portable test can detect poisonous mushrooms in minutes

New prophylactic and therapeutic avenues to fight against rabies

New prophylactic and therapeutic avenues to fight against rabies

New treatment effective at reversing the manifestations of thyroid eye disease

New treatment effective at reversing the manifestations of thyroid eye disease

New treatment target for acute kidney injury prevention revealed

New treatment target for acute kidney injury prevention revealed

Hendra antibody trial shows promise in a world-first human clinical trial

Hendra antibody trial shows promise in a world-first human clinical trial

New treatment target could change the outlook of patients at risk of kidney injury

New treatment target could change the outlook of patients at risk of kidney injury

Clinical trial to test safety, effectiveness of mAb against malaria in healthy volunteers

Clinical trial to test safety, effectiveness of mAb against malaria in healthy volunteers

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.